ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2037

Lipidomic Markers for Cognitive Impairment in Maintenance Hemodialysis Patients

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1300 Health Maintenance, Nutrition, and Metabolism


  • Zheng, Ke, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Qian, Yujun, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China
  • Li, Xuemei, Peking Union Medical College Hospital, Dongcheng-qu, Beijing, China

Cognitive impairment (CI) was relatively common in maintenance hemodialysis patients. The pathophysiology of CI in this particular population was not well understood. Whether the classic lipid components that affect cognitive outcome in general population have similar effect in dialysis patients is not clear. In this study, we tried to get a better understanding of the pathogenesis CI in hemodialysis patients by lipidomic analysis and find potential lipids markers to predict cognitive decline.


From July 2013 to July 2019, we followed up the cognitive evaluation results of the hemodialysis patients in our dialysis center. The cognitive function was evaluation by the MMSE and MoCA at baseline and follow-up period. Plasma and hemocytes of enrolled patients were collected at baseline. Lipidomic analyses were performed on an Exion LC-system coupled with a QTRAP 6500 PLUS system (Sciex). Principal component analysis and orthogonal project to late structures discriminant analysis, and t-test were used to analyze the differences in patients in cognitive decline group and cognitive retained group.


At the baseline, plasma from 21 patients and hemocytes from 65 patients were collected for lipidomic analyses. 539 lipids were detected in plasma and 237 lipids were detected in hemocytes. In individuals with plasma lipids files data, 10/21 suffered MMSE scores decrement and 16 /21 showed MoCA decrement. In patients with hemocytes lipids files date, 29/65 of them suffered MMSE scores decrement and 43/65 showed MoCA decrement.
Compared with retained MMSE scores group, decreased MMSE scores group presented higher level of plasma PA 32:1, PA 38:5, CE-17:1, and lower level of plasma DAG 40:6(18:0/22:6), PE 36:4(18:1/18:3). There was no significant difference in erythrocytes lipids between the two groups. Compared with retained MoCA scores group, decreased MoCA scores group presented higher level of plasma LacCer d18:1/18:0, LPE 18:2, GM3 d18:1/20:1, PE 36:3(18:1/18:2), LPE 18:1, lower level of plasma PI 38:5(18:0/20:5), and higher level of erythrocytes GM3 d18:0/20:0 (Fold change >1.5 or <1/1.5, P value <0.05).


The pathogenesis of CI in dialysis patients may closely relate with vascular injury. Lipid analysis may contribute to a new approach to predict the risk of cognitive decline in hemodialysis patients.